CANY
COLL icon

Caxton Associates (New York)’s Collegium Pharmaceutical COLL Stock Holding History

Caxton Associates (New York)’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-79,344
Closed -$3.07M – 521
2024
Q3 		$3.07M Buy
79,344
+25,733
+48% +$918K 0.11% 65
2024
Q2 		$1.73M Buy
53,611
+9,046
+20% +$314K 0.06% 168
2024
Q1 		$1.73M Buy
+44,565
New +$1.56M 0.1% 146

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Caxton Associates (New York)'s COLL Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Collegium Pharmaceutical (COLL) in Q4 2024, closing a stake of 79,344 shares — an estimated $3.07M sold.

Caxton Associates (New York) first reported a position in COLL in Q1 2024 and held it in 3 quarters. The position peaked at $3.07M in Q3 2024. 238 funds tracked by Wall St. Rank hold COLL as of Q4 2024.

  • Caxton Associates (New York) reported no remaining Collegium Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 79,344 Collegium Pharmaceutical shares in Q4 2024, an estimated $3.07M.
  • Caxton Associates (New York) first reported a position in Collegium Pharmaceutical in Q1 2024 and held it in 3 quarters.
  • Caxton Associates (New York)'s Collegium Pharmaceutical position peaked at $3.07M in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.